Sepsis Clinical Trial
Official title:
Effect of Automated Real-time Feedback on Early Sepsis Care
Verified date | November 2022 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Sepsis is the leading cause of death among US hospitals, accounting for 6% of all hospitalizations and 35% of all inpatient deaths. International guidelines and the CMS SEP-1 bundle stress the importance of adhering to specific steps in the diagnosis and management of sepsis. This can be very difficult, especially in the setting of a busy ED, ward, or ICU where there are multiple simultaneous demands on providers' attention and time. Critical steps can be missed or delayed. The CMS SEP-1 bundle is a measure of compliance with sepsis care that is being tracked nationally across hospitals. Unfortunately, a recent study demonstrated that every hour of delay to the completion of a sepsis bundle, including antibiotic administration, was associated with a 4% increase in risk-adjusted hospital mortality. One strategy to improve the care and outcomes of patients with sepsis is the use of information technology to support our providers in a targeted manner. Technology has already been developed and deployed to help with the early identification of patients with sepsis using a Best Practice Alert (BPA), which has been in place at our hospital since 2017. This pop-up window alerts the team to the possibility of sepsis based on data within the medical record. However, once the alert is accepted or declined, the BPA does not offer ongoing support to clinicians, leaving the clinician to track and execute multiple time-based and inter-dependent sepsis bundle measures in a busy, hectic environment. To augment this existing tool, here we propose to study the efficacy of a novel technology called the Sepsis Care Tracking Platform (SCTP) to provide ongoing support at the bedside to providers, thus improving the care we deliver to patients. SCTP is a monitoring and notification platform that aims to increase the timely delivery of key elements of evidence-based sepsis care. This platform, which was built by clinicians for clinicians, leverages the electronic medical record (EMR) to track real-time compliance with key components of the CMS SEP-1 bundle - timely antibiotics, blood cultures prior to antibiotics, initial lactate, and repeat lactate for those patients with an initially elevated level. SCTP underwent technical validation in Fall 2019 with a pilot in the MGH Emergency Department. The pilot confirmed that SCTP correctly identified missing bundle elements and paged the appropriate team members connected with the patient's care. The pilot also did not find alarm fatigue to be an issue. We hypothesize that SCTP will increase our hospital's compliance with sepsis process metrics and improve patient outcomes. By monitoring real-time data and automatically alerting bedside providers to missing elements within an actionable timeframe, SCTP has the potential to drive improvements in clinical care even in the extremely busy and complex environment of the emergency department and inpatient units.
Status | Completed |
Enrollment | 3269 |
Est. completion date | November 30, 2021 |
Est. primary completion date | November 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adult patients aged 18 years old and over 2. Who triggered a sepsis best practice advisory that was subsequently acknowledged by a treating clinician as "yes, sepsis possible" Exclusion Criteria: 1. Transfer from an outside hospital 2. Sepsis best practice advisory triggered while the patient is in an intensive care unit 3. Sepsis best practice advisory triggered while the patient is in a perioperative care area |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | Crico |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 3-hour sepsis bundle order compliance | Overall 3-hour bundle ordering compliance, defined as orders for all 3-hour bundle measures monitored by the study platform completed within the bundle time limits - i.e., orders for antibiotics, blood cultures, and lactate measurement measured from the electronic medical record at the end of the study period | Within 3 hours of sepsis BPA trigger (time zero) | |
Secondary | Antibiotic order compliance | Antibiotic ordering compliance, defined as orders for antibiotics placed within 3 hours of timezero | within 3 hours of timezero | |
Secondary | Blood culture order compliance | Blood culture ordering compliance, defined as orders for blood cultures placed within 3 hours of time-zero | within 3 hours of time-zero | |
Secondary | Initial lactate order compliance | Initial blood lactate level ordering compliance, defined as orders for initial blood lactate level within 3 hours of time-zero | within 3 hours of time-zero | |
Secondary | Repeat lactate order compliance | Repeat blood lactate level ordering compliance, defined as orders for repeat blood lactate level placed within 6 hours of time-zero and within 3 hours of initial lactate measurement, among patients with initial lactate > 2.0mmol/L | placed within 6 hours of time-zero and within 3 hours of initial lactate measurement | |
Secondary | 3-hour sepsis bundle care delivery compliance | Overall 3-hour bundle care delivery compliance, defined as the implementation of all 3-hour bundle measures monitored by the study platform completed within the bundle time limits - i.e., administration of antibiotics, collection of blood cultures prior to antibiotic administration, and lactate measurement. | Within 3 hours of sepsis BPA trigger (time zero) | |
Secondary | Antibiotic delivery compliance | Antibiotic delivery compliance, defined as administration of antibiotics within 3 hours of timezero | within 3 hours of timezero | |
Secondary | Blood culture delivery compliance | Blood cultures delivery compliance, defined collection of blood cultures within 3 hours of timezero and prior to antibiotic administration | within 3 hours of timezero and prior to antibiotic administration | |
Secondary | Initial lactate delivery compliance | Initial lactate delivery compliance, defined measurement of initial lactate within 3 hours of time-zero | within 3 hours of time-zero | |
Secondary | Repeat lactate delivery compliance | Repeat lactate delivery compliance, defined as the measurement of a repeat lactate within 6 hours of time-zero and within 3 hours of initial lactate measurement, among patients with an initial lactate > 2.0mmol/L | within 6 hours of time-zero and within 3 hours of initial lactate measurement | |
Secondary | Mortality by Day 28 | Mortality by Day 28 | Within 28 days of time zero | |
Secondary | Early mechanical ventilation | Early mechanical ventilation, defined as the receipt of mechanical ventilation or death within 72 hours of time-zero | within 72 hours of time-zero | |
Secondary | Early intensive care unit admission | Early intensive care unit (ICU) admission, defined as ICU admission or death within 72 hours of time-zero | within 72 hours of time-zero | |
Secondary | Mechanical ventilation during hospitalization | Mechanical ventilation during hospitalization, defined as receipt of mechanical ventilation or death within 28 days of time-zero | within 28 days of time-zero | |
Secondary | Early antibiotic discontinuation | Early antibiotic discontinuation, defined as discontinuation of all antibiotics for at least 24 hours by 48 hours post-time-zero | at least 24 hours by 48 hours post-time-zero | |
Secondary | Hospital length of stay | Hospital length of stay, defined as hospital days from time-zero through day 28 | Through day 28 after time zero | |
Secondary | Blood culture positivity | Blood culture positivity, defined as bacterial growth recovered from any blood culture collected 24 hours before or 7 days after time zero | 24 hours before or 7 days after time zero | |
Secondary | Non-blood culture positivity | Non-blood culture positivity, defined as bacterial pathogen recovery from any urine, respiratory, peritoneal, pleural, joint, or cerebrospinal fluid culture collected 24 hours before or 7 days after time zero | 24 hours before or 7 days after time zero | |
Secondary | Any culture positivity | Any culture positivity, defined as a composite of positive results from either the blood or non-blood culture positivity outcome | 24 hours before or 7 days after time zero |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |